

**Title:** Rehabilitation in Survivors of COVID-19 (RE2SCUE): a nonrandomized, controlled, and open protocol

**Authors:** Maria Cristine Campos, MSc<sup>a</sup>, Tatyana Nery<sup>a</sup>, Ana Cristina de Bem Alves, MSc<sup>a</sup>, Ana Elisa Speck, PhD<sup>a</sup>, Danielle Soares Rocha Vieira, PhD<sup>b</sup>, Ione Jayce Ceola Schneider, PhD<sup>b,c</sup>, Maria Paula Pereira Matos, MSc<sup>d</sup>, Livia Arcêncio, PhD<sup>b</sup>, Aderbal Silva Aguiar Junior, PhD<sup>a</sup>.

<sup>a</sup>Exercise Biology Lab (Labioex), Department of Health Sciences, Federal University of Santa Catarina, Araranguá, Brazil;

<sup>b</sup>Cardiovascular and Respiratory Assessment and Rehabilitation Lab (LaCOR), Department of Health Sciences, Federal University of Santa Catarina, Araranguá, Brazil;

<sup>c</sup>Epidemiological Research Lab (LabEpi), Department of Health Sciences, Federal University of Santa Catarina, Araranguá, Brazil;

<sup>d</sup>University of South Santa Catarina (Unisul), Psychology College, Santa Catarina, Tubarão, Brazil.

**Corresponding author:** A.S.Aguiar Jr, PhD, Labioex, Federal University of Santa Catarina, Pedro João Pereira, nº 150, Mato Alto - Araranguá - Santa Catarina, Brazil. CEP: 88.905-120. Address all correspondence to [aderbal.aguiar@ufsc.br](mailto:aderbal.aguiar@ufsc.br)

Trial registration number U1111-1261-4925

## Abstract

**Objective:** This study aimed to evaluate the effects of physical rehabilitation for adults with sequelae after COVID-19. **Methods:** This clinical, nonrandomized, controlled, and open study will examine 82 participants who have met the inclusion criteria and who will be divided into treatment and control groups according to participant preference. The intervention group will receive face-to-face care; the control group will receive remote educational guidance for 8 weeks, with pre-post evaluations. The primary outcomes are dyspnea, fatigue, and exercise capacity; the secondary outcomes are lung function, heart rate variability, handgrip strength, knee extensor strength and electrical activity, physical activity, functional limitation, cognitive function, depression and anxiety, and biochemical measures of hypoxia, inflammation, oxidative stress, blood glucose, and lactate blood tests. The survey will follow the *Standard Protocol Items for Randomized Trials* guidelines, and the results will be reported according to the *Consolidated Standards of Reporting Trials* guidelines. Effects will be assessed based on the intent-to-treat data collected. Analysis of covariance will be used for the initial and final evaluations, with a significance level of 5%. **Results and Conclusions:** The results will show the effectiveness of rehabilitation in adults with post-COVID-19 sequelae.

**Impact:** Fatigue, dyspnea, cough, and muscle and joint pain are common sequelae of post-COVID-19 syndrome. Physical rehabilitation is one modality for treating these sequelae. This protocol can provide a treatment model for patients with post-COVID-19 sequelae.

**Keywords:** Rehabilitation. Coronavirus. COVID-19. Respiratory Tract Diseases. Exercise therapy.

**Number of words:** 2.533

## **Introduction**

Coronavirus disease 2019 (COVID-19) is a global public health emergency<sup>(1)</sup> caused by coronavirus 2 that affects multiple organs and systems<sup>(2)(3)(4)(5)(6)</sup>. Similar to other infectious viral conditions, COVID-19 has caused persistent sequelae<sup>(5)</sup> regardless of disease severity<sup>(7)(8)</sup>. Post-acute symptoms include fatigue, headache, attention disorders, hair loss, dyspnea, cough, ageusia, anosmia, muscle and joint pain, and chest pain, persistent in 80% of individuals after the disease<sup>(7)(9)</sup>.

A prospective cohort study with 1,733 participants has shown that fatigue was the most reported symptom (63%), followed by difficulty sleeping, anxiety, and depression<sup>(10)</sup>. Furthermore, in nonhospitalized patients, dyspnea, fatigue, anosmia, and ageusia may persist for 4–7 months post-infection<sup>(8)</sup>. The late effects and presence of long-lasting symptoms characterize a post-acute COVID-19 syndrome<sup>(5)(9)(11)</sup>.

Impaired health and reduced functional capacity have demonstrated COVID-19's impact and the need to develop a safe, efficient rehabilitation protocol to recover function and social, professional, and family life<sup>(12)</sup>. Rehabilitation after recovery from acute COVID-19 has been recommended<sup>(1)(13)(14)(15)(16)(17)</sup> for different degrees of respiratory, physical, and psychological dysfunctions<sup>(1)(18)</sup>. The main rehabilitation objectives are to reduce dyspnea, improve functional capacity, reduce anxiety and depression, treat complications resulting from immobility, and facilitate return to social and work activities<sup>(1)(13)</sup>.

Some studies have shown that physical exercise can improve exercise capacity, reduce fatigue and respiratory symptoms, and improve cognition<sup>(19)</sup>, quality of life, and anxiety in these patients<sup>(20)</sup>. However, there is little evidence for rehabilitation safety and effectiveness in post-COVID-19 syndrome. Therefore, this study will investigate the effects of a rehabilitation protocol for adults and older people with post-acute COVID-19 syndrome who are in an extra-hospital environment that is centered on physical exercise, patient education, and lifestyle changes.

## **Methods**

### ***Study design***

This study is clinical, nonrandomized, controlled, and open. The research will follow the *Standard Protocol Items for Randomized Trials* (SPIRIT)<sup>(21)</sup>, and the results will be reported according to the *Consolidated Standards of Reporting Trials*<sup>(22)</sup>.

### ***Participant allocation***

A researcher will manage the participant allocation. The selected volunteers will be allowed to choose to participate in either the control (remote educational guidance) or intervention group (face-to-face physical rehabilitation) according to their preferences and availabilities. This nonrandomized allocation was determined after the pilot study indicated low adherence by the control group.

### ***Sample size calculation***

The sample size calculation is based on the functional capacity results assessed by the 6-min walking test from the 2020 study by Kai Liu et al.<sup>(20)</sup>. Considering a power of 80%, a significance level of 5%, and a 10% loss to follow-up, the estimation was 41 participants per group.

### ***Participant recruitment***

The clinical trial will be conducted at the Hospital Regional de Araranguá (HRA), a regional hub in the southern state of Santa Catarina, Brazil. Recruitment will be carried out from the COVID-19 register of the region's Health Department through phone and press calls and social networks. Participant inclusion and exclusion criteria are shown in Table 1.

Table 1.

### ***Participant discontinuity and adherence strategies***

Participants will be discontinued from treatment if a new adverse event, such as an additional COVID-19 infection, significant hemodynamic changes, and/or musculoskeletal injury prevent physical training.

A follow-up every 15 days will reinforce healthy habits and guidance on physical activities for the control group. At treatment's end, the participants will be invited to contribute an individualized satisfaction survey about their intervention. Justifications for study withdrawals will be reported. Participants can choose not to participate in some measures as registered on an informed-consent form.

### ***Group evaluation and assessment***

Trained physiotherapists will evaluate all participants pre- and posttreatment. Participants will receive care for 8 consecutive weeks (Fig. 1). Moreover, participants will undergo an electrocardiogram examination before treatment, with results reported by a cardiologist.

Figure 1.

The intervention group (n = 41) will undergo 8 consecutive weeks of physical rehabilitation, 2×/week, with an average duration of 60 min/session. The control group (n = 41) will receive educational guidance and assistance via video call, telephone, or text message and will also be instructed to improve their physical activity (PA).

### ***Intervention group treatment***

Participants in the intervention group will undergo rehabilitation supervised by physiotherapists. Hemodynamic parameters (blood pressure [BP], heart rate [HR]), peripheral oxygen saturation, and perceived exertion will be continuously monitored.

Aerobic exercise will be performed on a treadmill at moderate intensity at 60%–75% of the reserve HR calculated using the Karvonen method and 4–6 on a modified Borg scale rating of perceived exertion<sup>(23)</sup>. The initial treadmill speed will be 75% of the average speed reached in the incremental shuttle walk test (ISWT)<sup>(24)</sup>. Participants will perform 5 min of warming up and cooling down and 30 min of aerobic exercise.

The resistance exercises will be applied in 3 × 10 sets, with an initial 80% load of ten maximum repetitions for trunk and back and upper and lower limbs, with 1–2-min intervals between sets. Finally, the exercised muscles will be slightly stretched (30 s) at the end of the session. Figure 2 illustrates the intervention group's exercise protocol.

Figure 2.

If necessary, breathing exercises for expansion improvement and bronchial hygiene will be performed.

### ***Control group treatment***

A booklet with general guidelines on breathing etiquette, nutritional information, water intake, energy conservation techniques, breathing exercises, and PA will be provided to participants in the control group. Every fortnight, participants will receive a video call to reinforce the guidelines and monitor health status. For more details on the guidelines and SPIRIT Checklist, see the supplementary materials 1 and 2, respectively.

### ***Outcome measures***

#### *Primary measures*

The primary outcomes of the study are dyspnea, fatigue, and exercise capacity. Dyspnea symptoms will be assessed by the Medical Research Council scale. The Modified Pulmonary Functional Status Dyspnea Questionnaire will be used to evaluate dyspnea and fatigue in activities of daily living (ADLs)<sup>(25)</sup>.

Exercise capacity will be assessed using the ISWT, a progressive walking test with sound cues (beeps) and controlled speed, which is a valid and reliable evaluation of the functional capacity of respiratory patients<sup>(26)</sup>. The primary outcome will be the distance covered<sup>(26)</sup>. Two measurements will be taken, with the longest distance considered due to the learning effect (26)(27).

#### *Secondary measures*

Secondary outcome measures will be lung function, handgrip strength, knee extensor strength and electrical activity, functional status, anxiety and depression, PA, HR variability (HRV), cognitive function, and hypoxia, inflammation, oxidative stress, and blood lactate and glucose. A more detailed description of the measurements for each outcome is provided below. Figure 3 presents the model for collecting and analyzing the study data and the research development.

Figure 3.

**Lung function.** Spirometry will evaluate lung function following the Brazilian and international guidelines<sup>(28)(29)</sup>. The following variables will be considered: forced vital capacity (FVC), forced expiratory volume in 1 s, peak expiratory flow, and the

average forced expiratory flow between 25% and 75% of the FVC (25%–75%)<sup>(30)</sup>. The 2007 predicted values by Pereira et al. will be used<sup>(31)</sup>.

Handgrip strength. Following the American Society of Hand Therapy recommendations, handgrip strength will be assessed using a Jamar® dynamometer<sup>(32)</sup>. The participants will be seated in a chair with a backrest and without upper-limb support, feet flat on the floor, dominant shoulder in the adducted position, elbow flexed at 90°, and forearm in neutral<sup>(33)</sup>. Three maximum isometric contractions held for 6 s with an interval of 1 min will be collected.

Knee extensor strength and electrical activity. Knee extensor strength associated with surface electromyography will be evaluated through the maximum voluntary isometric contraction (MVIC) of the dominant lower limb<sup>(34)(35)</sup>. The NewMiotol digital converter will register the traction force in the Miograph software (force load cell model; Miotec Biomedical Equipment, Porto Alegre, Brazil). The electrodes will be attached to the quadriceps according to the Surface ElectroMyoGraphy for the Non-Invasive Assessment of Muscles specifications.

Participants will perform the test sitting in a chair with a backrest, 90° of hip flexion, 60° of knee flexion, and arms to the chest. With instruction and verbal encouragement, participants will perform as much isometric strength as possible for 6 s<sup>(36)(37)</sup>. The muscle fatigue test will be considered 50% of the MVIC, with ankle weights. Participants will perform the test until fatigue, defined by the loss of tibial tuberosity contact with a metal rod. The isometric contraction time until the point of fatigue will be registered<sup>(38)</sup>.

PA level. PA level will be evaluated by the ActiGraph® wGT3X-BT accelerometer (Pensacola, FL, USA). Participants will be instructed to use the instrument for 7 consecutive days. Data will be collected considering a sampling rate of 30 Hz and analyzed using a 60-s epoch. Periods of nonuse, defined as 60 min of consecutive 0 counts, with a peak acceleration tolerance of 2 min, will be excluded<sup>(39)</sup>. The PA level will be classified based on the adult recommendations<sup>(40)</sup>.

The data validated will be for those with 3 days of measurements, including 1 weekend day, with at least 10 h of daily use (or 600 min)<sup>(41)</sup>. Participants will receive written instructions, along with a diary for recording moments of nonuse.

Functional status. Functional status will be assessed by the Post-COVID-19 Functional Status Scale, composed of five levels (0–4), in which 0 corresponds to *the absence of functional limitation*, and 4 is *severe limitation with the need for assistance in all ADLs*<sup>(42)</sup>.

Cognitive function. Cognitive function will be assessed using memory prospective, retrospective, and focused attention tests. The Reminder Prospective Memory Test assesses prospective memory. Participants will be instructed to request the sending of a message by phone (WhatsApp) with the results of their vital signs before starting the field test (ISWT)<sup>(43)</sup>. The Red Pen Prospective Memory Test will instruct the participants to remember to request a red pen to complete the attention test, which is carried out afterward. The red pen will be kept in a drawer, while a blue one will be on the table<sup>(44)(45)</sup>.

The Brazilian version of the Rey Auditory–Verbal Learning Test will be used for retrospective memory assessment. This easy-to-apply test is widely recognized in the neuropsychological literature<sup>(46)</sup>.

Focused attention will be assessed using the Attention Test version R, “d2-R,” which consists of 1 page with 14 lines with the letters *d* and *p* distributed. The target symbol is a *d* with two dashes (d2). The objective is to strike as many targets as possible, constantly moving from left to right of the line, with a time limit of 20 s for each line attempt<sup>(47)</sup>.

Anxiety and depression. The assessment of anxiety and depression will be carried out using the Hospital Anxiety and Depression Scale<sup>(48)</sup>. The response scale for each item ranges from 0 to 3, with a total score for each subscale of 21 points<sup>(49)</sup>. Scores of  $\geq 8$  indicate anxiety and depression.

Anxiety symptoms will be assessed using the Anxiety Inventory for Respiratory Disease. Each item is scored from 0 (*no anxiety symptoms*) to 3 (*anxiety symptoms almost all the time*) points, with a total score of 0–30. A score of  $\geq 8$  suggests the presence of anxiety<sup>(50)</sup>.

HRV. HRV<sup>(51)</sup> will be measured by the V800 HR monitor (Polar Electro OY, Kempele, Finland)<sup>(52)</sup>. Participants will wear a chest strap with an HR sensor and a

wristwatch. The HRV recording will be performed with the participants in the supine position for 20 min at rest.

The data will be saved via the Polar Flow web service synchronized with the FlowSync software and analyzed by the Kubios HRV Standard software. Linear methods in time and frequency will be analyzed<sup>(51)</sup>.

Biochemical measurements of hypoxia, inflammation, oxidative stress, and blood glucose and plasma lactate. A blood sample will be collected in a specific hospital laboratory. Blood collection will be the first activity of the day, with no prior physical effort or need for fasting.

Subsequently, 10 mL of antecubital venous blood collected in EDTA heparinized tubes will be centrifuged with 6.6 µL of Histopaque® 1119 at 2,000 rpm for 30 min to obtain and store the plasma. Thereafter, leucocytes (next layer) will be transferred to a Falcon tube with 10 mL (qs) of 0.9% saline and centrifuged at 1,500 rpm for 10 min. The leucocyte pellets will then be collected for storage. If the pellet is not available, this process will be repeated with saline 1:10 of H<sub>2</sub>O Milli-Q®.

The last step requires discarding the remaining Histopaque from the primary tubes and adding 10 mL (qs) of 0.9% saline to the blood. After being homogenized 4×, these tubes will be centrifuged at 1,500 rpm for 10 min. After discarding the Histopaque®, the red blood cells will be collected and stored at -80°C, along with the plasma and leucocytes, until biochemical analysis.

Hypoxia (hypoxia factors 1 and 2, shock protein 70) and inflammation (interleukins 1β, 4, 6, and 10) markers will be analyzed with commercial enzyme-linked immunosorbent assay kits.

Capillary blood will be collected at the end of the ISWT to measure blood glucose with the G-TECH Lite monitor and a lactate analyzer (Lactate Detect TD-4261) in mmol/L.

#### ***Data monitoring committee***

This study will not have a data monitoring committee, considering that the exercises performed are of low-to-moderate intensity and will be supervised by experts<sup>(16)</sup>. The treatment session will always be held in the hospital's internal environment, where medical services specialized for urgencies and emergencies are immediately available.

In addition, all participants in both groups will be encouraged to report any discomfort during appointments.

### ***Statistical analysis***

A numbered ID will identify participants. Two independent team members will type the data collected on a computer and check for missing or erroneous values. In addition, all paper and electronic files will be kept in a safe place, with access restricted to the research team. The analysis will be carried out by a researcher blinded to the participants' allocation through the program Stata SE 16.1 (2020; StataCorp. College Station, TX, USA).

A significance level of 5% will be considered. The data will be presented as absolute and relative frequencies and as central tendency and dispersion measures. We will report 95% confidence intervals.

An intention-to-treat analysis will be held<sup>(53)</sup>. An analysis of covariance will be used to compare the control and intervention groups, with adjustments for the variables age, sex, and admission to the intensive care unit. The effect size will be calculated and classified as small (0.20–0.50), average (0.50–0.80), or large (>0.80)<sup>(54)</sup>.

### ***Role of the funding source***

The funding sources were Fundação de Amparo à Pesquisa e Inovação do Estado de Santa Catarina (FAPESC), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), and the Ministry of Health (Brazil). The funding sources will have no role in this study's design, conduct, or reporting.

### **Discussion**

The results will be analyzed, reviewed, and submitted to scientific journals. Semiannual meetings will occur during all study phases to follow up with the Ministry of Health and the CNPq.

This study provides a complete description of the rehabilitation protocol for adult patients with COVID-19 sequelae. The results will demonstrate the effects of rehabilitation, providing assessment and treatment methods and contributing to the

public health policies for patients with COVID-19 sequelae and to the clinical decisions of professionals who work directly in their physical rehabilitation.

Considering the impact of post-COVID-19 syndrome on the functionality of the affected patients, especially for fatigue and dyspnea, our study addresses a moderate-intensity exercise treatment as a central component of rehabilitation.

### **Acknowledgments**

The authors thank the volunteers, the Hospital Regional de Araranguá (HRA), and the funding sources.

### **Conflicts of interest**

The authors declare no conflicts of interest.

### **Ethics Approval**

This protocol was approved by the University's Ethics Research Committee (CAAE: 38682820.0.0000.0121) and is registered with the Brazilian Clinical Trials Registry (U1111-1261-4925). The study will be conducted according to Resolution 466/2012 of the National Health Council. All participants must sign an informed-consent form.

## References

1. Yang LL, Yang T. Pulmonary rehabilitation for patients with coronavirus disease 2019 (COVID-19) [Internet]. Vol. 6, Chronic diseases and translational medicine. KeAi Communications Co.; 2020 [cited 2021 Jul 5]. p. 79–86. Available from: <https://pubmed.ncbi.nlm.nih.gov/32411496/>
2. Zhang Y, Xiao L-S, Li P, Zhu H, Hu C, Zhang W-F, et al. Clinical Characteristics of Patients With Progressive and Non-progressive Coronavirus Disease 2019: Evidence From 365 Hospitalised Patients in Honghu and Nanchang, China. *Front Med*. 2020;7:556818.
3. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med* [Internet]. 2020 Apr 1 [cited 2021 Jul 5];8(4):420–2. Available from: <https://pubmed.ncbi.nlm.nih.gov/32085846/>
4. Gupta A, Madhavan M V., Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of COVID-19 [Internet]. Vol. 26, Nature Medicine. Nature Research; 2020 [cited 2021 Jul 5]. p. 1017–32. Available from: <https://pubmed.ncbi.nlm.nih.gov/32651579/>
5. Nalbandian A, Sehgal K, Gupta A, Madhavan M V., McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome [Internet]. Vol. 27, Nature Medicine. Nature Research; 2021 [cited 2021 Jul 5]. p. 601–15. Available from: <https://pubmed.ncbi.nlm.nih.gov/33753937/>
6. Willi S, Lüthold R, Hunt A, Hänggi NV, Sejdiu D, Scaff C, et al. COVID-19 sequelae in adults aged less than 50 years: A systematic review [Internet]. Vol. 40, Travel Medicine and Infectious Disease. Elsevier Inc.; 2021 [cited 2021 Jul 5]. p. 101995. Available from: [/pmc/articles/PMC7898978/](https://pubmed.ncbi.nlm.nih.gov/34017846/)
7. Salamanna F, Veronesi F, Martini L, Landini MP FM. Post-COVID-19 Syndrome: The Persistent Symptoms at the Post-viral Stage of the Disease. A Systematic Review of the Current Data. *Front Med* [Internet]. 2021 May 4 [cited 2021 Jul 12];8. Available from: <https://pubmed.ncbi.nlm.nih.gov/34017846/>
8. Augustin M, Schommers P, Stecher M, Dewald F, Gieselmann L, Gruell H, et

- al. Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. *Lancet Reg Heal – Eur* [Internet]. 2021 Jul 1 [cited 2021 Jul 12];6:100122. Available from: <http://www.thelancet.com/article/S2666776221000995/fulltext>
9. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. More than 50 Long-term effects of COVID-19: a systematic review and meta-analysis. *medRxiv Prepr Serv Heal Sci* [Internet]. 2021 Jan 30 [cited 2021 Jul 5]; Available from: <http://www.ncbi.nlm.nih.gov/pubmed/33532785>
  10. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *Lancet* [Internet]. 2021 Jan 16 [cited 2021 Jul 5];397(10270):220–32. Available from: <https://pubmed.ncbi.nlm.nih.gov/33428867/>
  11. Davis HE, Assaf GS, Mccorkell L, Wei H, Low RJ, Re'em Y, et al. Characterizing Long COVID in an International Cohort: 7 Months of Symptoms and Their Impact. *medRxiv* [Internet]. 2021 Apr 5 [cited 2021 Jul 5];2020.12.24.20248802. Available from: <https://doi.org/10.1101/2020.12.24.20248802>
  12. Singh SJ, Barradell AC, Greening NJ, Bolton C, Jenkins G, Preston L, et al. British Thoracic Society survey of rehabilitation to support recovery of the post-COVID-19 population. *BMJ Open*. 2020 Dec;10(12):e040213.
  13. Zhu Y, Wang Z, Zhou Y, Onoda K, Maruyama H, Hu C, et al. Summary of respiratory rehabilitation and physical therapy guidelines for patients with COVID-19 based on recommendations of World Confederation for Physical Therapy and National Association of Physical Therapy. *J Phys Ther Sci* [Internet]. 2020 [cited 2021 Jul 5];32(8):545–9. Available from: </pmc/articles/PMC7443542/>
  14. Zeng B, Chen D, Qiu Z, Zhang M, Wang G, Wang J, et al. Expert consensus on protocol of rehabilitation for COVID-19 patients using framework and approaches of WHO International Family Classifications. *AGING Med* [Internet]. 2020 Jun 1 [cited 2021 May 16];3(2):82–94. Available from:

<http://www.nhc>.

15. Zhao HM, Xie YX, Wang C. Recommendations for respiratory rehabilitation in adults with coronavirus disease 2019 [Internet]. Vol. 133, Chinese Medical Journal. Lippincott Williams and Wilkins; 2020 [cited 2021 Jul 5]. p. 1595–602. Available from: <https://pubmed.ncbi.nlm.nih.gov/32251002/>
16. Spruit MA, Holland AE, Singh SJ, Tonia T, Wilson KC, Troosters T. COVID-19: Interim guidance on rehabilitation in the hospital and post-hospital phase from a European Respiratory Society- And American Thoracic Society-coordinated international task force. Eur Respir J [Internet]. 2020 Dec 1 [cited 2021 Jul 5];56(6). Available from: [/pmc/articles/PMC7427118/](https://pubmed.ncbi.nlm.nih.gov/32251002/)
17. Barker-Davies RM, O’Sullivan O, Senaratne KPP, Baker P, Cranley M, Dharm-Datta S, Ellis H, Goodall D, Gough M, Lewis S, Norman J, Papadopoulou T, Roscoe D, Sherwood D, Turner P, Walker T, Mistlin A, Phillip R, Nicol AM, Bennett AN BS. The Stanford Hall consensus statement for post-COVID-19 rehabilitation. Br J Sports Med [Internet]. 2020 Aug 1 [cited 2021 Jul 12];54(16):949–59. Available from: <https://pubmed.ncbi.nlm.nih.gov/32475821/>
18. LI J. Rehabilitation management of patients with COVID-19: Lessons learned from the first experience in China. Eur J Phys Rehabil Med [Internet]. 2020 Jun 1 [cited 2021 Jul 5];56(3):335–8. Available from: <https://pubmed.ncbi.nlm.nih.gov/32329589/>
19. Daynes E, Gerlis C, Chaplin E, Gardiner N, Singh S. Early experiences of rehabilitation for patients post-COVID to improve fatigue, breathlessness exercise capacity and cognition. medRxiv [Internet]. 2021 Mar 28 [cited 2021 Jul 12];2021.03.25.21254293. Available from: <https://www.medrxiv.org/content/10.1101/2021.03.25.21254293v1>
20. Liu K, Zhang W, Yang Y, Zhang J, Li Y, Chen Y. Respiratory rehabilitation in elderly patients with COVID-19: A randomized controlled study. Complement Ther Clin Pract [Internet]. 2020 May 1 [cited 2021 Jul 5];39. Available from: <https://pubmed.ncbi.nlm.nih.gov/32379637/>
21. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K,

- et al. SPIRIT 2013 statement: Defining standard protocol items for clinical trials [Internet]. Vol. 158, *Annals of Internal Medicine*. American College of Physicians; 2013 [cited 2021 Jul 5]. p. 200–7. Available from: <https://pubmed.ncbi.nlm.nih.gov/23295957/>
22. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomised trials. *BMJ* [Internet]. 2010 Mar 27 [cited 2021 Jul 5];340(7748):698–702. Available from: <https://pubmed.ncbi.nlm.nih.gov/20332509/>
  23. Graves J.E., Pollock M.L. BC. Assessment of Muscular Strength and Endurance. In: William and Wilkins, editor. *ACSM Resource Manual Guidelines for Exercise Testing and Prescription*. 3rd ed. Baltimore; 1998. p. 363–367.
  24. Zainuldin R, Mackey MG, Alison JA. Prescription of walking exercise intensity from the incremental shuttle walk test in people with chronic obstructive pulmonary disease. *Am J Phys Med Rehabil*. 2012 Jul;91(7):592–600.
  25. Kovelis D, Segretti NO, Probst VS, Lareau SC, Brunetto AF, Pitta F. Validação do Modified Pulmonary Functional Status and Dyspnea Questionnaire e da escala do Medical Research Council para o uso em pacientes com doença pulmonar obstrutiva crônica no Brasil. *J Bras Pneumol* [Internet]. 2008 Dec [cited 2021 Jul 5];34(12):1008–18. Available from: <http://www.scielo.br/j/jbpneu/a/ydZrjfxcmgqDVLqjr3mgChs/abstract/?lang=pt>
  26. Holland AE, Spruit MA, Troosters T, Puhan MA, Pepin V, Saey D, et al. An official European respiratory society/American thoracic society technical standard: Field walking tests in chronic respiratory disease. *Eur Respir J* [Internet]. 2014 Dec 1 [cited 2021 Jul 5];44(6):1428–46. Available from: <https://pubmed.ncbi.nlm.nih.gov/25359355/>
  27. Singh SJ, Puhan MA, Andrianopoulos V, Hernandez NA, Mitchell KE, Hill CJ, et al. An official systematic review of the European Respiratory Society/American Thoracic Society: Measurement properties of field walking tests in chronic respiratory disease [Internet]. Vol. 44, *European Respiratory Journal*. European Respiratory Society; 2014 [cited 2021 Jul 5]. p. 1447–78.

Available from: <https://pubmed.ncbi.nlm.nih.gov/25359356/>

28. Alberto Castro Pereira C DE. Espirometria. In: Diretrizes para Testes de Função Pulmonar. Vol. 28, J Pneumol. 2002.
29. Brian L Graham, Irene Steenbruggen, Martin R Miller, Igor Z Barjaktarevic, Brendan G Cooper, Graham L Hall, Teal S Hallstrand, David A Kaminsky, Kevin McCarthy, Meredith C McCormack, Cristine E Oropez, Margaret Rosenfeld, Sanja Stanojevic, Maureen P Swann BRT. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. *Am J Respir Crit Care Med* [Internet]. 2019 Oct 15 [cited 2021 Aug 2];200(8):E70–88. Available from: <https://pubmed.ncbi.nlm.nih.gov/31613151/>
30. Sylvester KP, Clayton N, Cliff I, Hepple M, Kendrick A, Kirkby J, et al. ARTP statement on pulmonary function testing 2020. *BMJ Open Respir Res* [Internet]. 2020 Jul 5 [cited 2021 Jul 12];7(1):575. Available from: </pmc/articles/PMC7337892/>
31. De Castro Pereira CA, Sato T, Rodrigues SC. New reference values for forced spirometry in white adults in Brazil. *J Bras Pneumol* [Internet]. 2007 [cited 2021 Jul 5];33(4):397–406. Available from: <http://www.scielo.br/j/jbpneu/a/WVd7dxkTHbzzCVBfyzBt59v/abstract/?lang=pt>
32. Fess EE. Documentation: essential elements of an upper extremity assessment battery. In: St Louis: Mosby, editor. *Rehabilitation of the hand and upper extremity*. 5th ed. 2002. p. 263–84.
33. Amaral CA, Amaral TLM, Monteiro GTR, Vasconcellos MTL, Portela MC. Hand grip strength: Reference values for adults and elderly people of Rio Branco, Acre, Brazil. *PLoS One* [Internet]. 2019 Jan 1 [cited 2021 Jul 5];14(1). Available from: <https://pubmed.ncbi.nlm.nih.gov/30703162/>
34. Meldrum D, Cahalane E, Conroy R, Fitzgerald D, Hardiman O. Maximum voluntary isometric contraction: Reference values and clinical application. *Amyotroph Lateral Scler* [Internet]. 2007 [cited 2021 Jul 5];8(1):47–55. Available from: <https://pubmed.ncbi.nlm.nih.gov/17364436/>

35. Skrzat JM, Carp SJ, Dai T, Lauer R, Hiremath S V., Gaeckle N, et al. Use of Surface Electromyography to Measure Muscle Fatigue in Patients in an Acute Care Hospital. *Phys Ther* [Internet]. 2020 Jun 23 [cited 2021 Jul 5];100(6):897–906. Available from: <https://pubmed.ncbi.nlm.nih.gov/32157308/>
36. Meldrum D, Cahalane E, Keogan F, Hardiman O. Maximum voluntary isometric contraction: Investigation of reliability and learning effect. *Amyotroph Lateral Scler Other Mot Neuron Disord* [Internet]. 2003 [cited 2021 Jul 5];4(1):36–44. Available from: <https://pubmed.ncbi.nlm.nih.gov/12745617/>
37. Bachasson D, Villiot-Danger E, Verges S, Hayot M, Perez T, Chambellan A, et al. Mesure ambulatoire de la force maximale volontaire isométrique du quadriceps chez le patient BPCO. 2014 [cited 2021 Jul 5]; Available from: <https://hal.umontpellier.fr/hal-02565166>
38. Rondelli RR, Corso SD, Simões A, Malaguti C. Methods for the assessment of peripheral muscle fatigue and its energy and metabolic determinants in COPD [Internet]. Vol. 35, *Jornal Brasileiro de Pneumologia. Sociedade Brasileira de Pneumologia e Tisiologia*; 2009 [cited 2021 Jul 5]. p. 1125–35. Available from: <http://www.scielo.br/j/jbpneu/a/vRTVHTtqDtThpXDTcDnZVvKH/abstract/?lang=pt>
39. Sasaki J, Coutinho A, Santos C, Bertuol C, Minatto G, Berria J, et al. Orientações para utilização de acelerômetros no Brasil. *Rev Bras Atividade Física Saúde* [Internet]. 2017 Mar 1 [cited 2021 Jul 5];22(2):110–26. Available from: <https://rbafs.org.br/RBAFS/article/view/7452>
40. Freedson PS, Melanson E, Sirard J. Calibration of the Computer Science and Applications, Inc. accelerometer. *Med Sci Sports Exerc* [Internet]. 1998 [cited 2021 Jul 5];30(5):777–81. Available from: <https://pubmed.ncbi.nlm.nih.gov/9588623/>
41. Troiano RP, Berrigan D, Dodd KW, Mâsse LC, Tilert T, Mcdowell M. Physical activity in the United States measured by accelerometer. *Med Sci Sports Exerc* [Internet]. 2008 Jan [cited 2021 Jul 5];40(1):181–8. Available from: <https://pubmed.ncbi.nlm.nih.gov/18091006/>
42. Klok FA, Boon GJAM, Barco S, Endres M, Miranda Geelhoed JJ, Knauss S, et

- al. The post-COVID-19 functional status scale: A tool to measure functional status over time after COVID-19 [Internet]. Vol. 56, *European Respiratory Journal*. European Respiratory Society; 2020 [cited 2021 Jul 5]. Available from: <https://pubmed.ncbi.nlm.nih.gov/32398306/>
43. Cuttler C, Taylor S. Did I Forget to Lock the Door? The Link between Prospective Memory Failures and Doubt in the Compulsion to Check. *J Exp Psychopathol* [Internet]. 2012 Jul 1 [cited 2021 Jul 5];3(3):437–54. Available from: <https://journals.sagepub.com/doi/10.5127/jep.021811>
44. Dobbs AR, Rule BG. Prospective memory and self-reports of memory abilities in older adults. *Can J Psychol* [Internet]. 1987 [cited 2021 Jul 5];41(2):209–22. Available from: <https://pubmed.ncbi.nlm.nih.gov/3502897/>
45. Sng E, Frith E, Loprinzi PD. Temporal Effects of Acute Walking Exercise on Learning and Memory Function. *Am J Heal Promot* [Internet]. 2018 Sep 1 [cited 2021 Jul 5];32(7):1518–25. Available from: [https://journals.sagepub.com/doi/10.1177/0890117117749476?url\\_ver=Z39.88-2003&rfr\\_id=ori%3Arid%3Acrossref.org&rfr\\_dat=cr\\_pub++0pubmed](https://journals.sagepub.com/doi/10.1177/0890117117749476?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed)
46. Malloy-Diniz LF, Lasmar VAP, Gazinelli LDSR, Fuentes D, Salgado JV. The Rey Auditory-Verbal Learning Test: Applicability for the Brazilian elderly population. *Rev Bras Psiquiatr* [Internet]. 2007 [cited 2021 Jul 5];29(4):324–9. Available from: <https://pubmed.ncbi.nlm.nih.gov/17713697/>
47. Brickenkamp, R., Schmidt-Atzert, L. & L. Test d2-Revision: Aufmerksamkeits- und Konzentrationstest. Hogrefe, editor. Göttingen; 2010.
48. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. *Acta Psychiatr Scand* [Internet]. 1983 [cited 2021 Jul 5];67(6):361–70. Available from: <https://pubmed.ncbi.nlm.nih.gov/6880820/>
49. Botega NJ, Bio MR, Zomignani MA, Garcia C, Pereira WA. Mood disorders among inpatients in ambulatory and validation of the anxiety and depression scale HAD. *Rev Saude Publica* [Internet]. 1995 [cited 2021 Jul 5];29(5):355–63. Available from: <http://www.scielo.br/j/rsp/a/dY4tVF5tWXkrfkyjz5Sp4rM/abstract/?lang=pt>
50. Willgoss TG, Goldbart J, Fatoye F, Yohannes AM. The development and

- validation of the anxiety inventory for respiratory disease. *Chest* [Internet]. 2013 [cited 2021 Jul 5];144(5):1587–96. Available from: <https://pubmed.ncbi.nlm.nih.gov/23907347/>
51. Catai AM, Pastre CM, Godoy MF de, Silva E da, Takahashi AC de M, Vanderlei LCM. Heart rate variability: are you using it properly? Standardisation checklist of procedures [Internet]. Vol. 24, *Brazilian Journal of Physical Therapy. Revista Brasileira de Fisioterapia*; 2020 [cited 2021 Jul 5]. p. 91–102. Available from: <https://pubmed.ncbi.nlm.nih.gov/30852243/>
  52. Giles D, Draper N, Neil W. Validity of the Polar V800 heart rate monitor to measure RR intervals at rest. *Eur J Appl Physiol* [Internet]. 2016 Mar 1 [cited 2021 Jul 5];116(3):563–71. Available from: [/pmc/articles/PMC4751190/](https://pubmed.ncbi.nlm.nih.gov/2711190/)
  53. White IR, Horton NJ, Carpenter J, Pocock SJ. Strategy for intention to treat analysis in randomised trials with missing outcome data. *BMJ* [Internet]. 2011 Apr 23 [cited 2021 Jul 5];342(7803):910–2. Available from: <https://pubmed.ncbi.nlm.nih.gov/21300711/>
  54. Cohen J. *Statistical Power Analysis for the Behavioral Sciences*. 2nd ed. NJ: Lawrence Erlbaum Associates P, editor. Upper Saddle River; 1988.


## Tables and figures legends

**Table 1.** Study participants' inclusion and exclusion criteria. Legend: RT-PCR, reverse-transcriptase polymerase chain reaction; CVD, cardiovascular disease; COPD, chronic obstructive pulmonary disease; NYHA, New York Heart Association.

**Figure 1.** Schedule of participant enrollment, interventions, and assessments. Legend:  $-t_1$ , fulfillment of the inclusion criteria;  $t_1$ , initial evaluation;  $t_2$ , evaluation after 8 weeks of treatment;  $t_8$ , final evaluation.

**Figure 2.** Illustration of the intervention group's exercise protocol. The images illustrate (a) aerobic training on a treadmill, (b–f) active stretching, and (g–l) resistance exercises for the arms, legs, and chest muscles. *Source:* Authors (2021)

**Figure 3.** Flowchart of the study conduction process. *Source:* Authors (2021).



## STUDY PERIOD

	Enrolment	Allocation	Post-allocation	Close-out
TIMEPOINT	$-t_1$	0	$t_1$	$t_8$
<b>ENROLMENT:</b>				
<b>Eligibility screen</b>	X			
<b>Informed consent</b>		X		
<b>Allocation</b>		X		
<b>INTERVENTIONS:</b>				
<i>[Intervention]</i>			←→	
<i>[Control]</i>			←→	
<b>ASSESSMENTS:</b>				
<i>[Primary and Secondary outcomes]</i>			X	X